The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The AtheroRemo-IVUS study aims to investigate the relation of coronary plaque phenotype and vulnerability as determined by intravascular ultrasound and near infrared spectroscopy with genetic profile and novel circulating biomarkers. AtheroRemo-IVUS is a prospective, observational, cohort study of patients who underwent coronary catheterization for acute coronary syndrome or stable angina pectoris. Prior to the catheterization procedure, blood samples were drawn for biomarker measurements and genetic analyses. Subsequent to the catheterization procedure, intravascular ultrasound is performed in a non-culprit coronary artery. In patients who are also participating in the AtheroRemo-NIRS substudy, near-infrared spectroscopy is additionally performed in the same non-culprit vessel. Primary endpoint is the presence of vulnerable plaque as determined by intravascular ultrasound. Secondary endpoint is long-term incidence of major adverse cardiac events. Results from AtheroRemo-IVUS are expected to improve our knowledge on the role of genetic profile and inflammation in the development of atherosclerosis and vulnerable plaques. Furthermore, novel biomarkers and intracoronary imaging techniques will be validated in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tissue Characterization and Primary Percutaneous Coronary Intervention Guidance Using Intravascular Ultrasound

NCT05007535

ST Elevation Myocardial Infarction Acute Myocardial Infarction Coronary Artery Disease +3 more

UNKNOWN

IVUS Assessment of Atheroma Burden After Acute Coronary Syndrome

NCT01578005

Acute Coronary Syndrome

COMPLETED

Validation of vFFR as Compared to FFR to Guide Revascularization of Non-culprit Lesions in STEMI Patients

NCT05698719

ST Elevation Myocardial Infarction Multivessel Coronary Artery Disease Percutaneous Coronary Intervention

UNKNOWN

PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions

NCT05230446

Multi Vessel Coronary Artery Disease Non-ST Elevation Myocardial Infarction Unstable Angina +4 more

RECRUITING NA

Intravascular Identification and Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques

NCT04765956

Coronary Artery Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ATHEROREMO-IVUS cohort

Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.

Drawing blood samples

Intervention Type OTHER

Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure

Coronary intravascular ultrasound imaging

Intervention Type DEVICE

Coronary intravascular ultrasound imaging of a non-culprit coronary artery.

Coronary near-infrared spectroscopy

Intervention Type DEVICE

Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drawing blood samples

Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure

Intervention Type OTHER

Coronary intravascular ultrasound imaging

Coronary intravascular ultrasound imaging of a non-culprit coronary artery.

Intervention Type DEVICE

Coronary near-infrared spectroscopy

Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients of both sexes, more than 21 years old.
2. Patients with stable angina pectoris (CCS Class 1, 2, 3 or 4) or unstable angina pectoris (Braunwald Class 1-3, B-C) or patients with documented silent ischemia or patients with an acute myocardial infarction (STEMI and NSTEMI).
3. Patients eligible for coronary revascularization in the native coronary artery/arteries.
4. Willing and able to comply with the specified follow-up evaluation.
5. Written informed consent obtained.
6. Flow-limiting stenosis (diameter stenosis ≥50% by QCA or visual estimate) that is held responsible for angina pectoris or acute coronary syndrome
7. The study vessel has not undergone percutaneous coronary intervention in the last 8 months.

Exclusion Criteria

1. Braunwald class IA, IIA, IIIA (angina caused by non-cardiac illness).
2. Women who are pregnant or women of childbearing potential who do not use adequate contraception.
3. Known allergies to aspirin, clopidogrel bisulfate (Plavix ®), Ticlopdine (Ticlid ®) heparin, stainless steel, copper or a sensitivity to contrast media which cannot be adequately pre-medicated.
4. Previous participation in this study or participation in another study with any investigational drug or device within the past 30 days (study participation ends after completion of the final follow-up.)
5. Life expectancy of less than one year or factors making clinical and/or angiographic follow-up difficult.
6. Planned or being status post coronary bypass surgery.
7. Planned major non-cardiac surgery.
8. Impaired renal function (creatinine \>2 mg/dl or \>150 umol/L).
9. The subject has a history of bleeding diathesis or coagulopathy.
10. The subject suffered disabling stroke within the past year.
11. 3-vessel coronary artery and/or Left main disease with \> 50% stenosis.
12. Minimal lumen diameter \<2mm in the segments to be analyzed within the study vessel.
13. Diameter Stenosis \>70% or total occlusion of the study vessel.
14. In case the study-vessel has been stented previously (\>8 months ago), more than 1/3 proximal of the study vessel (at least 40mm in length) should be available for examination (i.e., outside the length of the stent plus 5mm proximal to the stent).
15. Poor LV function as assessed by Echo or by Angiography.
16. The proximal vessel is moderately to severely tortuous (moderate: 2 bends \>75 degrees or one bend \>90 degrees) in the segment(s) to be analyzed.
17. Known tendency to coronary vasospasm.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No